Revision within 6 years

By type of shoulder arthroplasty
Reverse total shoulder arthroplasty by demographics
Total anatomical shoulder arthroplasty by demographics

Shoulder » Survival » Revision within 6 years » By type of shoulder arthroplasty

FIGURE Cumulative revision percentage of primary shoulder arthroplasties by type of shoulder arthroplasty in the Netherlands in 2014-2020 (n=19,165)

TABLE Cumulative revision percentages of primary shoulder arthroplasties

	Number (n)	Number at risk (n)	Competing Risk¹ (95% CI)	Kaplan Meier (95% CI)
Primary shoulder arthroplasty	19,165
1-year revision (%)		15,736	2.3 (2.1-2.6)	2.4 (2.2-2.6)
3-year revision (%)		8,990	4.5 (4.2-4.9)	4.7 (4.3-5.0)
5-year revision (%)		3,734	5.6 (5.2-6.0)	5.9 (5.4-6.3)
6-year revision (%)		1,629	5.8 (5.4-6.3)	6.2 (5.7-6.7)
By type of primary shoulder arthroplasty
Reverse	12,891
1-year revision (%)		10,310	2.4 (2.2-2.7)	2.5 (2.2-2.8)
3-year revision (%)		5,563	3.7 (3.3-4.1)	3.9 (3.5-4.2)
5-year revision (%)		2,124	4.4 (4.0-4.9)	4.7 (4.2-5.2)
6-year revision (%)		884	4.6 (4.2-5.1)	4.9 (4.4-5.5)
Total anatomical	4,093
1-year revision (%)		3,514	1.6 (1.2-2.1)	1.6 (1.2-2.0)
3-year revision (%)		2,104	4.4 (3.7-5.1)	4.4 (3.7-5.1)
5-year revision (%)		922	5.7 (4.9-6.7)	5.8 (4.9-6.7)
6-year revision (%)		400	6.2 (5.3-7.4)	6.4 (5.3-7.5)
Hemi	2,086
1-year revision (%)		1,838	3.0 (2.4-3.9)	2.9 (2.2-3.7)
3-year revision (%)		1,266	8.9 (7.7-10.3)	9.0 (7.6-10.3)
5-year revision (%)		667	10.6 (9.2-12.2)	11.1 (9.6-12.7)
6-year revision (%)		335	10.8 (9.4-12.4)	11.3 (9.7-12.9)

¹ The cumulative revision percentage using the competing risk method is shown in the figure.
Please note: Dotted lines represent the upper and lower limits of the 95% confidence interval.
Reverse: reverse total shoulder arthroplasty; Total anatomical: total anatomical shoulder arthroplasty; Hemi: shoulder hemiarthroplasty. CI: confidence interval

In 2014-2020, 1,456 (7.6%) primary shoulder arthroplasties were implanted in patients who died within six years after the primary procedure.

Shoulder » Survival » Revision within 6 years » Reverse total shoulder arthroplasty by demographics

TABLE Cumulative 5-year revision percentage of primary reverse total shoulder arthroplasties by demographics in the Netherlands in 2014-2020

			Cumulative 5-year revision percentage
	Number (n)	Number at risk (n)	Competing Risk (95% CI)	Kaplan Meier (95% CI)
Total	12,891	2,124	4.4 (4.0-4.9)	4.7 (4.2-5.2)
Gender
Men	2,978	422	8.3 (7.2-9.6)	8.8 (7.6-10.0)
Women	9,902	1,696	3.3 (2.9-3.8)	3.5 (3.0-4.0)
Age (years)
<50	98	15	n.a.	n.a.
50-59	467	53	8.7 (6.0-12.5)	8.9 (5.6-12.1)
60-69	2,785	440	7.0 (5.9-8.4)	7.3 (6.0-8.6)
70-79	6,519	1,118	4.0 (3.4-4.6)	4.2 (3.6-4.8)
≥80	3,010	493	2.2 (1.7-2.8)	2.4 (1.8-3.0)
Diagnosis
Osteoarthritis	3,948	625	3.9 (3.2-4.8)	4.2 (3.3-5.1)
Other	8,912	729	4.8 (4.2-5.6)	4.9 (4.4-5.5)
ASA score
I	699	138	7.8 (5.5-11.2)	8.0 (5.2-10.8)
II	7,530	1,278	3.7 (3.2-4.3)	4.0 (3.4-4.5)
III-IV	4,500	511	5.0 (4.2-5.9)	5.5 (4.6-6.4)
Walch score
A1	5,797	1,152	4.5 (3.9-5.2)	4.8 (4.1-5.5)
A2	2,767	428	4.3 (3.5-5.4)	4.6 (3.5-5.6)
B1	1,117	230	3.9 (2.7-5.5)	4.3 (2.8-5.8)
B2	679	84	2.7 (1.5-4.8)	2.9 (1.2-4.5)
B3	231	33	n.a.	n.a.
C	147	5	n.a.	n.a.
Body Mass Index (kg/m²)
Underweight (≤18,5)	125	23	n.a.	n.a.
Normal weight (>18,5-25)	3,608	578	4.1 (3.3-5.0)	4.4 (3.5-5.4)
Overweight (>25-30)	4,973	819	4.3 (3.6-5.0)	4.5 (3.8-5.3)
Obesity (>30-40)	3,584	579	4.7 (4.0-5.6)	4.9 (4.1-5.8)
Morbid obesity (>40)	357	50	6.1 (3.7-10.2)	6.3 (3.0-9.6)
Smoking
No	11,380	1,784	4.3 (3.9-4.8)	4.6 (4.0-5.1)
Yes	1,230	212	5.8 (4.5-7.5)	6.0 (4.5-7.6)

Please note: n.a. if <50 cases were at risk; CI: confidence interval.

Shoulder » Survival » Revision within 6 years » Total anatomical shoulder arthroplasty by demographics

TABLE Cumulative 5-year revision percentage of primary total anatomical shoulder arthroplasties by demographics in the Netherlands in 2014-2020

			Cumulative 5-year revision percentage
	Number (n)	Number at risk (n)	Competing Risk (95% CI)	Kaplan Meier (95% CI)
Total	4,093	922	5.7 (4.9-6.7)	5.8 (4.9-6.7)
Gender
Men	1,209	261	6.4 (4.9-8.4)	6.5 (4.7-8.2)
Women	2,880	660	5.4 (4.5-6.6)	5.5 (4.4-6.6)
Age (years)
<50	226	47	n.a.	n.a.
50-59	711	148	8.7 (6.4-11.9)	8.8 (6.1-11.6)
60-69	1,586	373	6.3 (5.0-8.0)	6.4 (4.8-7.9)
70-79	1,247	284	3.5 (2.4-5.1)	3.6 (2.2-5.0)
≥80	320	70	3.3 (1.6-6.7)	3.4 (0.9-5.9)
Diagnosis
Osteoarthritis	3,422	723	5.1 (4.2-6.1)	5.1 (4.2-6.1)
Other	657	144	9.8 (7.2-13.3)	9.1 (6.4-11.7)
ASA score
I	576	138	7.4 (5.1-10.7)	7.2 (4.5-9.8)
II	2,699	601	5.9 (4.8-7.2)	6.1 (4.9-7.2)
III-IV	667	140	4.0 (2.6-6.0)	3.9 (2.2-5.5)
Walch score
A1	1,639	429	6.5 (5.2-8.1)	6.6 (5.1-8.1)
A2	1,158	251	5.4 (4.0-7.4)	5.5 (3.8-7.3)
B1	663	143	4.0 (2.5-6.2)	4.0 (2.2-5.8)
B2	283	46	n.a.	n.a.
B3	57	14	n.a.	n.a.
C	18	3	n.a.	n.a.
Body Mass Index (kg/m²)
Underweight (≤18,5)	18	6	n.a.	n.a.
Normal weight (>18,5-25)	993	221	5.7 (4.1-7.9)	5.8 (3.9-7.7)
Overweight (>25-30)	1,584	362	5.1 (3.9-6.7)	5.2 (3.8-6.6)
Obesity (>30-40)	1,286	261	6.9 (5.3-8.9)	7.0 (5.2-8.8)
Morbid obesity (>40)	122	34	n.a.	n.a.
Smoking
No	3,564	767	5.2 (4.3-6.2)	5.2 (4.3-6.2)
Yes	470	115	8.5 (5.8-12.4)	8.9 (5.5-12.3)

Please note: n.a. if <50 cases were at risk; CI: confidence interval.

This website is only accessable on large screens